Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.33 |
| ▸ | MDM4 | O15151 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 3/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5321491 | 0.89 | RAB9A (0.34) | RAB9ANPC1CLK1MEN1KMT2A | |
| SCHEMBL6112299 | 0.88 | RAB9A (0.33) | RAB9ANPC1CLK1MEN1KMT2A | |
| SCHEMBL27599399 | 0.82 | ACHE (0.34) | KMT2AMDM2MDM4TP53P2RY12 | |
| SCHEMBL5317843 | 0.80 | DPP4 (0.39) | — | |
| SCHEMBL5234053 | 0.78 | LMNA (0.34) | MEN1KMT2AMDM2MDM4TP53 | |
| SCHEMBL299730 | 0.78 | DPP4 (0.44) | RAB9ANPC1CLK1GAANPSR1 | |
| Hydrochloric Acid SCHEMBL5235399 | 0.77 | DPP4 (0.43) | RAB9ANPC1CLK1GAANPSR1 | |
| SCHEMBL5236366 | 0.75 | ABCB1 (0.38) | RAB9ANPC1CLK1GAAHTT | |
| SCHEMBL27582057 | 0.73 | DPP4 (0.42) | — | |
| SCHEMBL5238512 | 0.73 | DPP4 (0.34) | P2RY12HTTSMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | RAB9A 3400/4885NPC1 2372/4885CLK1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.